ITCI logo

Intra-Cellular Therapies (ITCI) Company Overview

Profile

Full Name:

Intra-Cellular Therapies, Inc.

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

United States

IPO:

January 7, 2014

Indexes:

Not included

Website:

http://www.intracellulartherapies.com

Description:

Intra-Cellular Therapies, Inc. is an American biopharmaceutical company. It has been in operation since 2001 and was officially registered in 2013 in the state of Delaware. The headquarters are located in New York. The company focuses on the development of small molecule drugs for the treatment of neuropsychiatric and neurological disorders. The drug candidate CAPLYTA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and is currently entering the commercialization phase. The drug candidate Lumateperone is intended for the treatment of depression associated with bipolar disorders, as well as for the treatment of agitation in patients with dementia, including Alzheimer's disease.

Key Details

Price

$128.16

Market Cap

$13.59 B(Large cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$462.18 M(+85.51% YoY)

Annual EPS

-$1.46(+46.32% YoY)

PE Ratio

-

Annual ROE

-22.39%

Annual Debt To Equity

0.00

Beta

0.36

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 31, 25 Canaccord Genuity
Hold
Jan 22, 25 RBC Capital
Sector Perform
Jan 14, 25 Piper Sandler
Neutral
Jan 13, 25 Needham
Hold
Nov 4, 24 JP Morgan
Overweight
Oct 31, 24 Needham
Buy
Oct 30, 24 Needham
Buy
Oct 11, 24 Morgan Stanley
Overweight
Oct 4, 24 RBC Capital
Outperform
Sep 20, 24 Cantor Fitzgerald
Overweight

Screeners with ITCI included

Growing Shares Outstanding
US stocks
Most recommended stocks
Stocks at all time highs
Best performing stocks last 3 months
Best performing stocks last 5 years
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$128.16
ITCI price is $128.16

Price All-time High

$128.16
ITCI price is currently at an all-time high

Price Analysts Target

$132.00
ITCI price is currently -2.91% lower than the consensus analysts' forecast

Price Most Recent Change

+0.23%
ITCI price was up +0.23% on Feb 19, 2025

Price YTD Change

+53.52%
ITCI price is up +53.52% since January 1st

Price 3-Year Change

+126.31%
ITCI price is up +126.31% over the past 3 years

Market cap

Market Cap

$13.59 B
ITCI market capitalization is $13.59 billion

Market Cap 3-Year Change

+158.43%
ITCI market capitalization is up +158.43% over the past 3 years

Market Cap All-time High

$13.59 B
ITCI market capitalization is currently at an all-time high

Market Cap Sector Rank

93.66%
ITCI market capitalization is higher than 93.66% of companies in Healthcare sector

Technical

Beta

0.36
ITCI beta is 0.36

200-day SMA

$83.16
ITCI price is currently +54.12% above its 200-day simple moving average

14-day RSI

84.27
ITCI 14-day relative strength index is 84.27

30-day Relative Volume

0.47
ITCI 30-day relative volume is 0.47

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$462.18 M
ITCI annual revenue is $462.18 million

Annual Revenue Analysts Estimate

$674.97 M
ITCI annual revenue is currently -31.53% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+85.51%
ITCI annual revenue is up +85.51% year-on-year

Annual Revenue Sector Rank

74.58%
ITCI annual revenue is higher than 74.58% of companies in Healthcare sector

Profit

Annual Gross Profit

$428.43 M
ITCI annual gross profit is $428.43 million

Annual Gross Margin

92.70%
ITCI annual gross profit margin is 92.70%

Annual Operating Profit

-$159.38 M
ITCI annual operating income is -$159.38 million

Annual Operating Margin

-34.49%
ITCI annual operating profit margin is -34.49%

Annual Net Income

-$139.67 M
ITCI annual net profit is -$139.67 million

Annual Net Margin

-30.22%
ITCI annual net profit margin is -30.22%

EPS

Annual EPS

-$1.46
ITCI annual earnings per share is -$1.46

Annual EPS Analysts Estimate

-$0.71
ITCI annual earnings per share is currently +105.95% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+46.32%
ITCI annual earnings per share is up +46.32% year-on-year

Annual EPS Sector Rank

51.26%
ITCI annual earnings per share is higher than 51.26% of companies in Healthcare sector

ROA & ROE

Annual ROA

-18.84%
ITCI annual return on assets is -18.84%

Annual ROE

-22.39%
ITCI annual return on equity is -22.39%

EBIT & EBITDA

Annual EBIT

-$159.38 M
ITCI annual earnings before interest & taxes is -$159.38 million

Annual EBITDA

-$158.85 M
ITCI annual EBITDA is -$158.85 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
ITCI price to earnings ratio value is unknown

PE Ratio Sector Rank

-
ITCI price to earnings ratio is unknown

PB Ratio

PB Ratio

11.87
ITCI price to book ratio is 11.87

PB Ratio Sector Rank

92.44%
ITCI price to book ratio is higher than 92.44% of companies in Healthcare sector

PS Ratio

PS Ratio

22.17
ITCI price to sales ratio is 22.17

PS Ratio Sector Rank

84.83%
ITCI price to sales ratio is higher than 84.83% of companies in Healthcare sector

Enterprise value

Enterprise Value

$13.14 B
ITCI enterprise value is $13.14 billion

Enterprise Value Sector Rank

94.03%
ITCI enterprise value is higher than 94.03% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-108.52
ITCI EV/EBITDA is -108.52

EV/EBITDA Sector Rank

1.31%
ITCI EV/EBITDA is higher than 1.31% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

5.41
ITCI annual current ratio is 5.41

Annual Quick Ratio

5.31
ITCI annual quick ratio is 5.31

Leverage

Annual Debt To Equity

0.00
ITCI annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
ITCI annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

4
ITCI piotroski f-score is 4

Altman Z-Score

57.26
ITCI altman z-score is 57.26

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$728.29 M
ITCI annual total assets is $728.29 million

Annual Non Current Assets

$60.50 M
ITCI annual long term assets is $60.50 million

Annual Current Assets

$667.80 M
ITCI annual total current assets is $667.80 million

Annual Cash & Cash Equivalents

$147.77 M
ITCI annual cash & cash equivalents is $147.77 million

Equity

Annual Book Value

$591.42 M
ITCI annual book value is $591.42 million

Annual Working Capital

$544.25 M
ITCI annual working capital is $544.25 million

Liabilities

Annual Total Liabilities

$136.87 M
ITCI annual total liabilities is $136.87 million

Annual Total Long Term Liabilities

$13.33 M
ITCI annual total long term liabilities is $13.33 million

Annual Current Liabilities

$123.55 M
ITCI annual total current liabilities is $123.55 million

Annual Accounts Payable

$11.45 M
ITCI annual accounts payable is $11.45 million

Debt

Annual Total Debt

$16.94 M
ITCI annual total debt is $16.94 million

Annual Total Debt 1-Year Change

-15.48%
ITCI annual total debt is down -15.48% year-on-year

Annual Long Term Debt

$13.33 M
ITCI annual long term debt is $13.33 million

Annual Short Term Debt

$3.61 M
ITCI annual short term debt is $3.61 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$621.56 M
ITCI annual total expenses is $621.56 million

Annual Operating Expenses

$587.81 M
ITCI annual total operating expenses is $587.81 million

Annual Cost Of Goods Sold

$33.74 M
ITCI annual cost of goods sold is $33.74 million

Annual SGA

$409.86 M
ITCI annual SGA is $409.86 million

Annual D&A

$528.00 K
ITCI annual depreciation & amortization is $528.00 thousand

Annual Interest Expense

-
ITCI annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$124.20 M
ITCI annual cash flow from operations is -$124.20 million

Annual CFO 1-Year Change

+54.03%
ITCI annual cash flow from operations is up +54.03% year-on-year

Annual CFI

$105.54 M
ITCI annual cash flow from investing activities is $105.54 million

Annual CFI 1-Year Change

+182.21%
ITCI annual cash flow from investing activities is up +182.21% year-on-year

Annual CFF

$17.81 M
ITCI annual cash flow from financing activities is $17.81 million

Annual CFF 1-Year Change

-96.09%
ITCI annual cash flow from financing activities is down -96.09% year-on-year

Free CashFlow

Annual FCF

-$124.47 M
ITCI annual free cash flow is -$124.47 million

Annual FCF 1-Year Change

+54.06%
ITCI annual free cash flow is up +54.06% year-on-year

CAPEX

Annual CAPEX

$269.00 K
ITCI annual capital expenditures is $269.00 thousand

Annual CAPEX 1-Year Change

-65.42%
ITCI annual capital expenditures is down -65.42% year-on-year

Institutional Ownership

Similar stocks

INCY logo
Incyte (INCY)
FMS logo
Fresenius Medical Care AG & Co KGaA (FMS)
BMRN logo
BioMarin Pharmaceutical (BMRN)
MRNA logo
Moderna (MRNA)
GMAB logo
Genmab A/S (GMAB)
RVTY logo
Revvity (RVTY)
RPRX logo
Royalty Pharma (RPRX)
VTRS logo
Viatris (VTRS)
TEM logo
Tempus AI (TEM)

FAQ

  • What is the ticker symbol for Intra-Cellular Therapies?
  • Does Intra-Cellular Therapies pay dividends?
  • What sector is Intra-Cellular Therapies in?
  • What industry is Intra-Cellular Therapies in?
  • What country is Intra-Cellular Therapies based in?
  • When did Intra-Cellular Therapies go public?
  • Is Intra-Cellular Therapies in the S&P 500?
  • Is Intra-Cellular Therapies in the NASDAQ 100?
  • Is Intra-Cellular Therapies in the Dow Jones?
  • When was Intra-Cellular Therapies's last earnings report?
  • When does Intra-Cellular Therapies report earnings?
  • Should I buy Intra-Cellular Therapies stock now?

What is the ticker symbol for Intra-Cellular Therapies?

The ticker symbol for Intra-Cellular Therapies is NASDAQ:ITCI

Does Intra-Cellular Therapies pay dividends?

No, Intra-Cellular Therapies does not pay dividends

What sector is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Healthcare sector

What industry is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Drug Manufacturers - Specialty & Generic industry

What country is Intra-Cellular Therapies based in?

Intra-Cellular Therapies is headquartered in United States

When did Intra-Cellular Therapies go public?

Intra-Cellular Therapies's initial public offering (IPO) was on January 7, 2014

Is Intra-Cellular Therapies in the S&P 500?

No, Intra-Cellular Therapies is not included in the S&P 500 index

Is Intra-Cellular Therapies in the NASDAQ 100?

No, Intra-Cellular Therapies is not included in the NASDAQ 100 index

Is Intra-Cellular Therapies in the Dow Jones?

No, Intra-Cellular Therapies is not included in the Dow Jones index

When was Intra-Cellular Therapies's last earnings report?

Intra-Cellular Therapies's most recent earnings report was on Oct 30, 2024

When does Intra-Cellular Therapies report earnings?

The next expected earnings date for Intra-Cellular Therapies is Feb 21, 2025

Should I buy Intra-Cellular Therapies stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions